Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Vandana Singh

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months

  • The FDA has granted emergency use authorization (EUA) to Pfizer Inc (NYSE:PFE) and BioNTech SE's (NASDAQ:BNTX) COVID-19 Vaccine as a three 3-µg dose series for children six months through 4 years of age. 
  • Based on safety, tolerability, and immunogenicity data, the 3-µg dose was carefully selected as the preferred dose for children under five.
  • The EUA is based on data from a Phase 2/3 trial that included 4,526 children six months through 4 years of age. In the trial, children received the third 3-µg dose at least two months after the second dose at a time when omicron was the predominant variant. 
  • Following the third dose in this age group, the vaccine elicited a robust immune response, with a favorable safety profile similar to a placebo.
  • No new safety signals were identified, and the frequency of adverse reactions observed in children six months through 4 years was generally lower than in children 5 through 11 years. 
  • Pfizer and BioNTech will begin shipping 3-µg pediatric doses as directed by the U.S. government.
  • The companies plan to submit requests for authorization of their COVID-19 vaccine in this age group to other regulators worldwide, including the European Medicines Agency, in early July.
  • Price Action: PFE shares are down 1.11% at $46.96, and BNTX stock is down 0.77% at $128.66 during the market session on the last check Friday.
  • Image by x3 from Pixabay
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.